Document Detail

Atherothrombotic events in rheumatoid arthritis are predicted by homocysteine - a six-year follow-up study.
MedLine Citation:
PMID:  19917166     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The aim of this study was to investigate whether homocysteine is linked to atherothrombotic (AT) events in patients with rheumatoid arthritis (RA). METHODS: Analysis of homocysteine (Hcy) levels was carried out in 235 consecutive RA patients. They were followed-up for 6.5 years or until death, with analysis of AT risk factors and the type and length of DMARD and corticosteroid treatment. The disease history before inclusion was collected. Six categories of AT events were defined. In addition, the diagnosis of the patients at follow-up was co-analyzed with the nationwide population-based Swedish Inpatient Register and Death Register to certify all events. RESULTS: The Hcy level was found to be higher in males (p<0.05) and increased with age (p<0.001). Patients with folic acid supplementation had significantly lower levels, while those on corticosteroids had higher levels. High Hcy levels predicted AT events (n=48) during a 6.5-year follow-up adjusted for age and male sex in a logistic regression analysis. CONCLUSION: In this study, RA patients on folic acid had lower Hcy levels. High Hcy levels (in addition to age, sex and diabetes) predicted AT event prospectively.
S Berglund; A S?dergren; S W?llberg Jonsson; S Rantap?? Dahlqvist
Related Documents :
20156946 - Patient-derived joint counts are a potential alternative for determining disease activi...
6785436 - D-penicillamine-induced increase in intracellular glutathione correlating to clinical r...
20639266 - Predicting arthritis outcomes--what can be learned from the leiden early arthritis clinic?
22955176 - Apoe4 predicts amyloid-β in cortical brain biopsy but not idiopathic normal pressure h...
2752776 - Comparison of two impedance cardiographic techniques for measuring cardiac output in cr...
11060826 - Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental rheumatology     Volume:  27     ISSN:  0392-856X     ISO Abbreviation:  Clin. Exp. Rheumatol.     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2009-11-17     Completed Date:  2010-03-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8308521     Medline TA:  Clin Exp Rheumatol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  822-5     Citation Subset:  IM    
Department of Public Health and Clinical Medicine, Rheumatology, University Hospital, Ume?, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Distribution
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / blood*,  complications,  drug therapy
Biological Markers / blood
Coronary Artery Disease / blood*,  complications
Dietary Supplements
Folic Acid / therapeutic use
Follow-Up Studies
Homocysteine / blood*
Middle Aged
Predictive Value of Tests
Sex Distribution
Reg. No./Substance:
0/Antirheumatic Agents; 0/Biological Markers; 454-28-4/Homocysteine; 59-30-3/Folic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low levels of endothelial progenitor cells correlate with disease duration and activity in patients ...
Next Document:  Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polya...